Nitin Kamath and Kiran Mazumdar-Shaw raise concerns over India’s GLP-1 slowdown
Show Quick Read Key points generated by AI, verified by newsroom India's GLP-1 weight-loss drug market faces weaker-than-expected demand. Drugmakers ...
Show Quick Read Key points generated by AI, verified by newsroom India's GLP-1 weight-loss drug market faces weaker-than-expected demand. Drugmakers ...
MarketsStocksHere are seven major companies whose stocks moved on the week’s news
MarketsHeard on the StreetBig Pharma has taken much of the heat for sky-high insulin prices, but scrutiny could soon shift ...